Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
Makaleler > Tam Makale · 2017
Yazarlar: B. Schultheis, D. Reuter, M.P. Ebert, J. Siveke, A. Kerkhoff, W.E. Berdel, R. Hofheinz, D.M. Behringer, W.E. Schmidt, Erdem GÖKER, S. De Dosso, M. Kneba, S. Yalcin, F. Overkamp, F. Schlegel, M. Dommach, R. Rohrberg, T. Steinmetz, M. Bulitta, D. Strumberg
Annals of Oncology, Uluslararası, Wos, 2017, cilt 28, ss 2429-2435